1. 329PAbemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET). (23rd October 2018) Authors: Grischke, E-M; Neven, P; Lin, Y; Kaufman, P A; Sledge, G W Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 339PManagement of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2- advanced breast cancer: Analysis of the MONARCH trials. (23rd October 2018) Authors: Rugo, H S; Tolaney, S M; Huober, J; Toi, M; André, V; Barriga, S; Forrester, T; Sledge, G W; Goetz, M P Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗